WallStSmart

AbbVie Inc (ABBV)vsAmerican Shared Hospital Service (AMS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 216115% more annual revenue ($62.82B vs $29.05M). ABBV leads profitability with a 5.8% profit margin vs -5.3%. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

AMS

Hold

36

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.0Quality: 4.0
Piotroski: 4/9Altman Z: 0.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-55.6%)

Margin of Safety

-55.6%

Fair Value

$146.00

Current Price

$227.23

$81.23 premium

UndervaluedFair: $146.00Overvalued
AMSUndervalued (+28.0%)

Margin of Safety

+28.0%

Fair Value

$3.18

Current Price

$1.33

$1.85 discount

UndervaluedFair: $3.18Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.3/10
Market CapQuality
$380.57B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
32.2%10/10

Strong operational efficiency at 32.2%

Debt/EquityHealth
-11.0210/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.598/10

Growing faster than its price suggests

Free Cash FlowQuality
$3.56B8/10

Generating 3.6B in free cash flow

AMS2 strengths · Avg: 9.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
105.1x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-46.2%2/10

Earnings declined 46.2%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

AMS4 concerns · Avg: 2.3/10
Market CapQuality
$9.08M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.5%2/10

ROE of -6.5% — below average capital efficiency

EPS GrowthGrowth
-38.1%2/10

Earnings declined 38.1%

Altman Z-ScoreHealth
0.972/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.

Bull Case : AMS

The strongest argument for AMS centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.

Bear Case : AMS

The primary concerns for AMS are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ABBV profiles as a value stock while AMS is a growth play — different risk/reward profiles.

AMS carries more volatility with a beta of 0.32 — expect wider price swings.

AMS is growing revenue faster at 15.9% — sustainability is the question.

ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (63/100 vs 36/100) and 12.4% revenue growth. AMS offers better value entry with a 28.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

American Shared Hospital Service

HEALTHCARE · MEDICAL CARE FACILITIES · USA

American Shared Hospital Services rents radiosurgery and radiation therapy equipment to healthcare providers. The company is headquartered in San Francisco, California.

Want to dig deeper into these stocks?